Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
July 22 2009 - 6:30AM
PR Newswire (US)
Conference Call and Webcast to Follow THE WOODLANDS, Texas, July 22
/PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
(NASDAQ:LXRX) will release its second quarter 2009 financial
results on Tuesday, July 28, 2009 before the financial markets
open. Lexicon management will hold a conference call to discuss its
clinical development progress and financial results for second
quarter 2009 at 11:00 a.m. Eastern Time on July 28, 2009. The
dial-in number for the conference call is 888-220-1244 (within the
US/Canada) or 706-679-5615 (international). The conference ID for
all callers is 17788499. Investors can access a live webcast of the
call at http://www.lexpharma.com/. An archived version of the
webcast will be available on the website through August 4, 2009.
About Lexicon Lexicon is a biopharmaceutical company focused on
discovering and developing breakthrough treatments for human
disease. Lexicon currently has five drug candidates in development
for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and
irritable bowel syndrome, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout
technology to identify more than 100 promising drug targets.
Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information about
Lexicon and its programs, please visit http://www.lexpharma.com/.
Safe Harbor Statement This press release contains "forward-looking
statements," including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors that may cause Lexicon's actual results to
be materially different from any future results expressed or
implied by such forward-looking statements. Information identifying
such important factors is contained under "Factors Affecting
Forward-Looking Statements" and "Risk Factors" in Lexicon's annual
report on Form 10-K for the year ended December 31, 2008, as filed
with the Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.
DATASOURCE: Lexicon Pharmaceuticals, Inc. CONTACT: Jason Ray,
Manager, Corporate Communications and Investor Relations of Lexicon
Pharmaceuticals, Inc., +1-281-863-3225, Web Site:
http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024